Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma.
Treatment of pancreatic cancer is increasingly multimodal, with patients receiving chemotherapy, radiation, and surgical extirpation in hope of long-term cure. There is ongoing debate over the timing, sequence, and necessity of these treatments as they pertain to the spectrum of local-regional disease. Current guidelines support a neoadjuvant strategy in patients with locally advanced and borderline resectable disease. Although there is currently no high-level evidence to recommend neoadjuvant therapy for all patients, there are data to suggest that wider application of neoadjuvant therapy may be beneficial. Random-assignment prospective trials are ongoing. In this review we examine the literature addressing a neoadjuvant approach to potentially resectable, borderline resectable, and locally advanced pancreatic cancer and highlight the outcomes of preoperative emergence of latent metastatic disease, attempted resection rates, margin negative resection rates, and pathologic response to treatment.
Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, NY.
Megan
M
Winner
Dana-Farber Cancer Institute, Boston, MA.
Stephanie L
SL
Goff
Division of Gastrointestinal/Endocrine Surgery, Pancreas Center, and Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, NY. Electronic address: Jac4@cumc.columbia.edu.
John A
JA
Chabot
D021441:Carcinoma, Pancreatic Ductal / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D020360:Neoadjuvant Therapy; D010190:Pancreatic Neoplasms / Q000628:therapy*